替比夫定联合胸腺肽α-1治疗慢性乙型肝炎患者80例疗效分析

doi:10.3969/j.issn.1672-5069.2016.06.019

Abstract

Jiang Hai, Xue Mingyue.. Prevalence of cardiovascular diseases in patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 715-716.

[1] Liaw YF，Chu CM. Hepatitis B virus infection. Lancet，2009，373（9663）:582-592.
[2] World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 dex. WHO Web site.Http://www.who.int/mediacentre/factsh eets/fs204/en/index.html.
[3] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[4] 李春玉，张学武，胡国启. 阿德福韦酯联合苦参素治疗慢性乙型肝炎的临床研究. 实用肝脏病杂志，2008，11：370-372.
[5] Villeneu JP，Condreay LD，Willems B，et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology，2000，31（1）:207-210.
[6] Lai CL，Leung N，Teo EK，et al. A 1-year trial of telbivudine，lamivudine，and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology，2005，129:528-536.
[7] 朱玫.抗乙型肝炎病毒治疗对自然病程的影响.肝脏，2007，12（增刊）：33-36.
[8] Thongsawat S，Lai CL，Gane E，et al. Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B:results from the globe study. Hepatology，2006，44（Suppl 2）:S49-S56.
[9] Behnava B，Alavian SM，Ahmadzad AM. The prevalence of thrombocytopenia in patients with chronic hepatitis B and C. Hepat Mon，2006，6（2）:67-69.
[10] Amarapurkar DN，Amarapurkar AD. Extrahepatic manifestations of viral hepatitis. Ann Hepatol，2002，1（4）:S556-S557.
[11] 任金才，宋建华，宋铮，等.恩替卡韦治疗慢加亚急性乙型肝炎肝衰竭临床观察.实用肝脏病杂志，2015，18（6）：603-606.
[12] 高海兵，林明华，潘晨，等.核苷类药物治疗 HBV 相关慢加急性肝衰竭患者24个月的生存分析.中华肝脏病杂志，2015，23（1）：17-22.
[13] 占国清，谭华炳，李儒贵，等.慢性乙型肝炎患者凝血功能和血小板参数检测结果分析. 实用肝脏病杂志，2011，14（6）：412-414.
[14] Philips CA，Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol，2014，20（43）:16037-16052.
[15] 吴家箴，杨兴祥，江南，等.应用核苷类似物治疗慢加急性乙型肝炎肝衰竭患者短期疗效观察.实用肝脏病杂志，2015，18（4）：413-415.
[16] 徐启桓，许镇，舒欣，等.抗病毒治疗对不同分期的乙型肝炎相关慢加急性肝衰竭患者短期生存率的影响.中山大学学报（医学科学版），2010，31（3）：381-384.

Prevalence of cardiovascular diseases in patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[5]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[6]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[7]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[8]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[9]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[10]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[14]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.